Maricann: A Unique & Undervalued Licensed Producer with a Global Focus -- CFN Media
May 29, 2018 08:40 ET
|
CFN Media
Seattle, WA. , May 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced...
Only 14 Percent of Organizations Fully Prepared for GDPR Requirements Despite Enforcement Later This Month
May 10, 2018 08:00 ET
|
HyTrust
MOUNTAIN VIEW, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- HyTrust announced today results from a survey of security professionals revealing that only 14 percent of organizations believe that they are...
Psychological Effects of Ovarian Cancer Often Overlooked and Can Have a Significant Impact on Patients
May 08, 2018 09:19 ET
|
TESARO, Inc.
79% of patients felt uncomfortable raising psychological and emotional concerns during their consultations1Disease recurrence is of greatest concern for ovarian cancer patients, but poorly addressed,...
DISC Publisher, PeopleKeys, Announces GDPR Readiness
May 02, 2018 02:00 ET
|
PeopleKeys
Youngstown, Ohio USA, May 02, 2018 (GLOBE NEWSWIRE) -- PeopleKeys, the leader in behavioral instruments and understanding, is proud to announce its preparation for the new landmark data privacy...
Global Insurance Symposium Announces Final Keynote on General Data Protection Regulation and the European Union
April 23, 2018 17:45 ET
|
Global Insurance Symposium
DES MOINES, Iowa, April 23, 2018 (GLOBE NEWSWIRE) -- The 2018 Global Insurance Symposium (GIS) today announced Aegon Global Chief Technology Officer and Member of the Management Board, Mark Bloom,...
TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
December 15, 2017 04:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker statusZEJULA is the only PARP inhibitor to...
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
November 20, 2017 07:00 ET
|
TESARO, Inc.
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker statusApproval supported by robust data from a randomized,...
CloudMe and Globell launch a secure joint European Cloud for the German speaking market
June 07, 2017 08:58 ET
|
Xcerion AB
Linköping/Tegelen, EU, June 07, 2017 (GLOBE NEWSWIRE) -- CloudMe, Europe’s leading provider of cloud sync and storage, with over 1.5 million subscribers, and Globell, the software distributor...
Kanguru: Why Non-EU Organizations Can’t Afford To Ignore GDPR
May 31, 2017 07:00 ET
|
Kanguru Solutions
MILLIS, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- One of the biggest changes in data security regulations is coming out of the European Union that will have a significant impact on organizations...
bioAffinity Technologies Announces Award of European Union Patent
May 03, 2017 14:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, May 03, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath®...